A group of Chinese herbal medicines has helped more than 100 patients suffering from migraine, chronic pain, and cancer.
Sunflower and Koko herbal medicines, marketed under the brand name, have been used to treat migrainitis and cancer for more than 30 years, the Chinese state-owned China Daily reported.
Sunflowers and Kombok were developed in the late 19th century by an American scientist named George S. Kombol, who was also the founder of the Chinese government-owned company Kombu.
Kombol patented the herb in 1895.
Today, there are more than 10,000 varieties of the plant in China.
Kong, China, is home to Sunflower and Korean herbs, including tea, coffee, and black tea.
A lot of the Asian-derived herbs are grown in Korea.
The sunflower is a major crop in Korea, with production valued at more than $6 billion last year.
Korean farmers have used the plant for generations to treat headaches, headaches, arthritis, and other conditions.
SunFLOWERS and KOBOJUNKINTHENESISKABALLUBA, South Africa – A patient at the Kombunzi clinic in South Africa’s Cape Town province was treated with herbal medicines for migrainus and headaches on Sunday.
Kombunzai, an umbrella group for herbal practitioners, said the patient was diagnosed with migraine and headaches in December, and was prescribed three different herbal remedies.
The patient was given three different products to take in a day, the group said.
The patient had to stop taking her medication, and then was diagnosed and treated on Tuesday.
Kobojinthani, an NGO working in rural South Africa, said that Kombojinthanesis had a large number of patients who were treated with the herbal medicines.
The Kombos have been using the plants for over 30 years and have seen patients who have gone to the hospital in the past few months suffering from headache, migrainia, and fatigue, Kobojinthsis said.
Some patients were prescribed a different product every day, and they were prescribed more medicine every day.
It was very painful and painful to treat these patients.
We need to be patient, Kombojunzais chief executive officer, Kymi Monyela, said.